- Trials with a EudraCT protocol (5)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
5 result(s) found for: HLA DR4.
Displaying page 1 of 1.
EudraCT Number: 2004-002571-16 | Sponsor Protocol Number: MBP8298-01 Amendment 04 | Start Date*: 2007-06-29 | |||||||||||
Sponsor Name:BioMS Technology Corp | |||||||||||||
Full Title: A double-blind, placebo controlled multicentre study to evaluate the efficacy and safety of MBP8298 in subjects with secondary progressive multiple sclerosis. | |||||||||||||
Medical condition: Secondary progressive multiple sclerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) SE (Completed) FI (Completed) DK (Completed) ES (Completed) EE (Completed) NL (Completed) LT (Prematurely Ended) LV (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2005-001621-29 | Sponsor Protocol Number: 80804002 | Start Date*: 2009-05-05 |
Sponsor Name:Faculty of Medicine Carl Gustav Carus, University of Technology, Dresden | ||
Full Title: Pre-POINT (Primary Oral INsulin Trial) study A dose finding safety and immune efficacy study for primary mucosal insulin therapy in islet autoantibody negative children at high genetic risk for ty... | ||
Medical condition: pre-type 1 diabetes (islet autoimmunity in non-diabetic relatives of subjects with type 1 diabetes) | ||
Disease: | ||
Population Age: Children, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Completed) AT (Completed) GB (Completed) | ||
Trial results: View results |
EudraCT Number: 2020-001317-20 | Sponsor Protocol Number: IMCY-T1D-003 | Start Date*: 2020-09-11 | |||||||||||
Sponsor Name:Imcyse SA | |||||||||||||
Full Title: A Phase Ib/IIa, randomized, double-blind placebo-controlled, multicenter adaptive design clinical trial to evaluate the immune signature of the treatment with the Imotope™ IMCY-0098 and its effect ... | |||||||||||||
Medical condition: Type 1 Diabetes | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) SI (Completed) LT (Prematurely Ended) IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-003088-36 | Sponsor Protocol Number: GPPAD-03-POInT | Start Date*: 2018-01-30 | |||||||||||
Sponsor Name:Technische Universität München, Represented by the school of medicine | |||||||||||||
Full Title: GPPAD-POInT (Global Platform of Autoimmune Diabetes – Primary Oral Insulin Trial) Oral Insulin Therapy for Prevention of Autoimmune Diabetes | |||||||||||||
Medical condition: risk for type 1 diabetes | |||||||||||||
|
|||||||||||||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Completed) GB (GB - no longer in EU/EEA) PL (Completed) DE (Completed) BE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-003028-30 | Sponsor Protocol Number: 808040019 | Start Date*: 2015-11-02 |
Sponsor Name:Technische Universität München, Fakultät für Medizin | ||
Full Title: Fr1da Insulin Intervention - Mechanistic study using oral insulin for immune and treatment efficacy in secondary prevention of type 1 diabetes | ||
Medical condition: Risk for type 1 diabetes | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
• EEA CTAs: Date study was authorised to proceed
• Outside EU/EEA: Date study was submitted in EudraCT
• Outside EU/EEA: Date study was submitted in EudraCT
